Pulsatile insulin
Pulsatile intravenous insulin therapy, also called metabolic activation therapy, delivers insulin in bursts rather than as a continuous drip. This approach aims to mimic how the pancreas normally releases insulin into the liver after meals.
Why pulses might help: In healthy people, insulin release changes with food amount. Continuous exposure to insulin and glucagon can reduce how well they work. Delivering insulin in pulses may help insulin receptors recover and work better, and bursts of insulin could more effectively reduce how much glucose the liver makes.
How it’s meant to work: Insulin normally travels from the pancreas to the liver through the portal vein. The liver is a key target for insulin’s effects on glucose metabolism. For the liver to regulate glucose well, a certain insulin level in the portal vein is needed, especially when glucose is high. About half of portal insulin is cleared in the first pass through the liver, so the liver gets a strong dose early on.
Limitations and evidence: Traditional subcutaneous insulin injections don’t mimic the natural pulsatile pattern and may not achieve high enough insulin levels in the liver. Reviews of the medical evidence have generally found insufficient proof that pulsatile insulin delivery provides clear benefits. As a result, many insurers do not cover the treatment. In some cases, court decisions have ordered coverage, but the Centers for Medicare & Medicaid Services (CMS) concluded there’s no solid evidence that pulsatile insulin improves type 1 or type 2 diabetes, and issued a nationwide non-coverage policy. There is a billing code for the treatment to avoid misbilling.
Bottom line: Pulsatile insulin therapy is an experimental approach with limited proven benefit so far. Major health programs have not accepted it as standard treatment, and more high-quality trials are needed to determine its effectiveness.
This page was last edited on 2 February 2026, at 11:37 (CET).